The National Blood Authority (NBA) has announced the outcome of its recent tender process for extended half life clotting factor products today. You will see the relevant document on the NBA website.
This means that there is funded access to extended half life factor VIII for all people with haemophilia A and an extended half life factor IX for all people with haemophilia B where they and their treating doctor at their Haemophilia Treatment Centre consider it for their treatment. Due to COVID-19 and some other local reasons there may be some delays to access; however, those who have been waiting for this development should speak with their doctor at their Haemophilia Treatment Centre.
This announcement does not include a decision about government funding for Hemlibra (emicizumab) which is registered in Australia for the treatment of people with severe and moderate haemophilia A with and without inhibitors. Hemlibra is not on the National Product List. HFA will continue to advocate for Hemlibra to be funded as well as the products on this list for our community.
